Sage Journals: Discover world-class research

Abstract

Objectives

This study examines the effects of cyclophosphamide, a cancer treatment that also functions as a cytotoxic agent, on the nephrotic system. The extent to which stem cell applications can be effective in preventing nephrotoxicity caused by agents is also a subject of investigation. The extent to which the nephrotoxic effects detected in the animal model treated with cyclophosphamide can be prevented by stem cell application will be investigated.

Material and Methods

A total of 18 Sprague Dawley rats were included in the study, divided into 3 groups. Group 1 consisted of the control group, which received intraperitoneal (IP) saline injection. Group 2-cyclophosphamide and Group 3-cyclophosphamide + stem cell was administered IP cyclophosphamide (50 mg/kg cyclophosphamide on the first day and then 8 mg/kg intraperitoneally for 14 days) to create a nephrotoxicity model. Group 3-cyclophosphamide + stem cell also received weekly hUCMSC 10*6 IP for 2 weeks. 4 weeks after the treatment, the animals were euthanized, their kidney tissues were histopathologically and immunohistochemically evaluated, and their blood values were biochemically evaluated.

Result

In histopathological examination, glomerulosclerosis and tubular damage were seen the most in Group 2, and this difference was found to be statistically significant (p<0.001 and p<0.01). However, no statistically significant difference was observed in terms of inflammation in the kidney tissues (p=0.068). No significant change was observed in the biochemically evaluated BUN, creatinine, or urea levels in all three groups (p<0.8; p<0.141; p<0.8).

Conclusion

In light of the current information, human Umbilical Cord Mesenchymal Stem Cell (hUC-MCS) has been demonstrated to reduce the nephrotoxicity caused by cyclophosphamide given for cytotoxic purposes on the kidney and exhibit induced renal regeneration. Our findings create new hope for the use of stem cell therapies in the field of kidney diseases.

Keywords

nephrotoxicity cyclophosphamide stem cell renal regeneration

Introduction

Cyclophosphamide (CTX) is widely used in cancer treatment and has many side effects, primarily nephrotoxicity and hepatotoxicity.¹ Today, cyclophosphamide is widely used as a chemotherapeutic agent, alone or in combination. It is used as an immunosuppressant especially in acute and chronic leukemias; ovarian cancers; multiple myeloma; lymphoma; testicular, small cell lung, and breast cancers; as well as organ transplantation; rheumatoid arthritis; systemic lupus erythematosus; and multiple sclerosis.^2,3

The two active metabolites of cyclophosphamide are phosphoramide mustard and acrolein. The antineoplastic effects of cyclophosphamide are related to phosphoramide mustard. It is thought that phosphoramide mustard suppresses cell division by binding to DNA and mediating the immunosuppressive and antitumor effects of cyclophosphamide. The toxic effect of cyclophosphamide is related to its active metabolite, acrolein 4. Acrolein inhibits P-450 by alkylating sulfhydryl groups⁵ and metabolizing glutathione via rapid modification of sulfhydryl groups to form mercapturic acid, which is excreted in urine.⁶ These metabolites cause both hepatic and renal damage. The renal pathological damage process caused by CTX is mediated by apoptosis and necrosis of renal tubular epithelial cells,⁷ release of inflammatory factors, and inflammatory response.⁸

Stem cells are cells that can self-renew, differentiate into multiple cell types, and proliferate to produce and renew different types of tissues and organs. Stem cells are used in the treatment of many diseases.^5-7 In addition, stem cell transplantation is performed after CTX in some cancer treatment protocols.⁸ While research has explored strategies for the treatment of both hepatotoxicity^9-11 and nephrotoxicity,^12-14 we have not come across any reports investigating the efficacy of stem cell therapies in cyclophosphamide treatment. Stem cell therapies are used after cyclophosphamide in the treatment protocol of some cancer diseases.¹⁵ In addition, stem cells have paracrine effects by promoting their differentiation capacity into other cells and generating immune regulatory, anti-inflammatory, anti-apoptotic, and anti-oxidative effects.^16,17 Stem cells also have analgesic and angiogenic effects.¹⁸ Preclinical studies demonstrate that mesenchymal stem cell therapy induces maximal functional and histological recovery during the intermediate phase (7–14 days) by enhancing tubular epithelial proliferation, suppressing apoptosis, and improving microvascular integrity, while long-term benefits observed after 14–28 days include attenuation of fibrosis, reduced TGF-β signaling, and prevention of progression to chronic kidney damage.^19,20Due to the regeneration properties of stem cells, damaged tissues can be renewed and repaired. In this study, we aimed to investigate the efficacy of umbilical cord-derived mesenchymal stem cells in animals with renal damage induced by CTX.

Material and Methods

Formation of Cyclophosphamide-Induced Kidney Injury Model and Administration of h-USMSC

A total of 18 female Sprague Dawley rats that were 9–10 weeks old and weighed 200–220 g were used in the study. The animals were obtained from the Gazi University Laboratory Animal Breeding and Experimental Research Centre and studied in the same laboratory. The animals were randomly divided into 3 groups. Group 1 (control group) received 2 cc 0.9% saline infusion intraperitoneally. For the kidney injury models, Groups 2 and 3 were injected with 50 mg/kg cyclophosphamide (Endoxan, EIP ECZACIBAŞI, Istanbul, Turkey) on the first day, and then 8 mg/kg intraperitoneal cyclophosphamide (CTX) was injected into the animals for 14 days. Group 3 was then injected with 0.6ml×10⁵/μL human Umbilical Cord Mesenchymal Stem Cell (hUC-MCS) intraperitoneally once a week for 2 weeks.

After inducing kidney damage with cyclophosphamide in the CTX and CTX+ Stem Cell groups, the CTX+Stem cell group received a total of 2 weeks of stem cell therapy. Four weeks after the last h-USMSC injection, the animals were euthanized., animals were euthanized by intracardiac blood sampling under xylazine (5 mg/kg, i.m) and ketamine (45 mg/kg, i.m) anesthesia. Blood samples were obtained via cardiac puncture for biochemical analysis. Kidney tissues were then removed and fixed in formaldehyde.

Ethical Approval

The study was approved by the Gazi University Animal Experiments Local Ethics Committee (Approval number: G.Ü.E.T-66332047-604.01-1015251).

Isolation and Characterization of h-USMSC

The h-USMSC used in our study was provided by STEMBIO-Cord Blood, Cell and Tissue Center, a GMP-certified company that produces stem cells and stem cell products. The necessary characterizations related to h-USMSC were performed in GMP-certified laboratories.

Removal, transfer, and decontamination of the tissues: The cord tissues of the subjects who applied to the cord blood bank were cleaned with 70% ethanol and then surgically cut and taken into a cord tissue transfer kit immediately after birth and delivered to the GMP laboratory. The tissue was first removed from the transfer kit and then was washed in a sterile petri dish (Falcon 100 mm-353003) with normal saline (0.9% isotonic sodium chloride solution-Polifarma/c-1911002). Thereafter, it was divided into fragments of 0.2 cm. These fragments were treated with normal saline containing a 4% antibiotic solution (P0781 Sigma-Aldrich Penicillin-Streptomycin). The umbilical cord tissue belongs to donor 1425 02 L.

Primary Culture

For primary culture, the tissue was cultured for 21 days in a complete medium [MSC Nutristem Basal Medium 05-200-1A Biological Industries MSC Nutristem Supplement 05-201-1U) +10% autologous plasma]. The obtained tissues were cultured under standard primary culture conditions at 5% carbon dioxide and 37 degrees Celsius. After 21 days, tissue fragments were removed, and the split process was performed until reaching passage 3 (P3). Subsequently, they were aliquoted into sterile vials to achieve a concentration of one million cells per milliliter (ml) for the experiment. The vials were then transferred under cold chain conditions to the animal experimentation unit. Tissue collection and culture procedures were conducted at Stembio Cord Blood, Cell, and Tissue Center under Good Manufacturing Practice (GMP) conditions.

Mesenchymal Stem Cell Immunophenotyping

After the primary culture, cells were collected into a polystyrene tube of 5 mL (BD 352003) so that there were 200,000 cells in each tube. For each sample, three tubes were prepared.20 microliters of anti-CD34 (BD Pharmingen PE Mouse Anti-Human CD34 Cat No. 560941) and anti-CD-45 (BD Pharmingen FITC Mouse Anti-Human CD45 Catalog No. 555482) were added to the 1st tube; anti-CD44 (BD Pharmingen FITC Mouse Anti-Human CD44 Catalog No 560977), anti-CD-73 (BD Pharmingen PE Mouse Anti-Human CD73 Cat No 550257), and anti-CD105 (BD Pharmingen APC Mouse Anti- Human CD105 Cat No. 562408) were added to the 2nd tube, and isotypic controls (Mouse IgG1, κ) were added to the 3rd tube for each fluorochrome. These were incubated at room temperature in the dark for 20 min. Following incubation, the cells were washed twice with sterile PBS, and flow cytometry (Becman Coulter Navios EX) analysis was performed.

Histological Examination of Rat Kidneys

Kidneys were fixed with 4% paraformaldehyde and embedded in paraffin for pathological analysis. Paraffin blocks were cut into 4-μm thick sections and stained with hematoxylin and eosin (H&E) and caspase. Histopathological evaluation was performed by a pathologist blinded to the experimental groups. To evaluate kidney function, BUN (blood urea nitrogen), urea, and creatinine levels were checked at 6 weeks in Groups 1, 2 and 3. Histopathologically, the degree of tubular atrophy was examined at four stages (0–25%, 25–50%, 50–75%, and 75–100%) and scored between 0–3. The presence of glomerulosclerosis was divided into 4 stages (0-25%, 25-50%, 50-75%, and 75-100%) and scored between 0–3 according to the percentage of presence in the examined area. Those with and without inflammation were graded as 0 and 1, respectively.

Elisa

Whole blood samples from the study groups were centrifuged at 3500 rpm for 10 minutes to separate the sera. Humor samples were stored in a -80◦C deep freezer until the day of the study together with aqueous humor samples. Serum samples were measured using the BT Lab (Zhejiang, China) brand kit using the sandwich ELISA principle. The experiment was performed according to the instructions of the commercial kit. A standard graph was drawn according to the absorbance in the standard samples, and the absorbance values read in the samples were substituted into this graph to calculate the concentrations.

Statistical Analysis

An a priori power analysis was performed using G*Power 3.1.9.7 software. The sample size was estimated based on a one-way ANOVA framework, adjusted for non-parametric analysis. For a large effect size (f=0.40) and 0.80 power, the required total sample size was 66. After applying the Asymptotic Relative Efficiency (ARE) correction of 15% for the Kruskal-Wallis test, the ideal sample size was calculated as approximately 76. However, as this was a pilot exploratory study and considering the 3R principles (Reduction), we proceeded with n=6 per group. This approach was sufficient to detect significant histopathological differences, Data were analyzed using non-parametric methods due to the small sample size (n=6). Kruskal-Wallis test was employed for inter-group comparisons of biochemical and histopathological data. Had significant differences been detected in biochemical markers, Dunn’s multiple comparison test would have been used for post-hoc analysis. Categorical data were analyzed using Fisher’s Exact Test.

The variables examined in the study glomerulosclerosis, tubal damage, and inflammation are categorical in nature, and their distributions were compared across three different groups (Control, CTX, and CTX + stem cell). These variables typically have between 2 to 4 levels and exhibit ordinal categorical structure (e.g., scores ranging from 0 to 3). Due to the relatively small sample sizes in each group and the presence of expected cell frequencies below 5 in some contingency tables, the assumptions of the chi-square test could not be met. Therefore, the Fisher’s Exact Test, a more appropriate and sensitive alternative for small sample sizes, was used to assess group differences. Otherwise, a statistical significance was measured between the variables. All analyses were conducted using the R programming language.

Results

When BUN, creatinine, and urea levels were evaluated biochemically in the three groups, no significant change was observed (Table 1).

Table 1.

Comparison of Biochemical Parameters Between Groups

Variables	Control	CTX	CTX + stem cell	p-value
Variables	N = 6	N = 6	N = 5	p-value
Creatinine				0.8
Mean (SD)	0.39 (0.03)	0.39 (0.07)	0.39 (0.07)
Median (IQR)	0.40 (0.39, 0.40)	0.37 (0.34, 0.46)	0.37 (0.34, 0.42)
Range	0.34, 0.42	0.31, 0.48	0.32, 0.49
Blood urea nitrogen (mg/dL)				0.141
Mean (SD)	26.3 (2.2)	23.3 (2.9)	23.8 (2.6)
Median (IQR)	26.0 (25.0, 27.0)	23.5 (23.0, 25.5)	23.0 (22.0, 26.0)
Range	24.0, 30.0	18.0, 26.0	21.0, 27.0
Blood urea level (mg/dL)				0.8
Mean (SD)	51.9 (1.2)	51.6 (7.3)	50.9 (5.5)
Median (IQR)	51.2 (51.0, 53.0)	53.5 (49.8, 55.6)	49.2 (47.1, 55.6)
Range	51.0, 53.5	38.5, 59.2	44.9, 57.8

In histopathological evaluation, in the Group 1 control group, 3 samples (60%) showed Stage 0 and 2 samples (40%) showed Stage 1 glomerulosclerosis. In the Group 2 cyclophosphamide group, 4 samples (80%) showed Stage 2 and 1 sample (20%) showed Stage 3 glomerulosclerosis. In the Group 3 cyclophosphamide + stem cell therapy group, 5 samples (100%) showed Stage 1 glomerular sclerosis, and the difference was statistically significant (p<0.001). When tubular atrophy was evaluated, in Group 1, 2 samples (40%) showed Stage 0 and 3 samples (60%) showed Stage 1. In Group 2, 3 samples (60%) showed Stage 2 and 2 samples (40%) showed Stage 3. In Group 3, 4 samples (80%) were detected as Stage 1 and 1 sample (20%) as Stage 2. The observed differences were statistically significant (p=0.010).

The presence of inflammation was observed in 2 samples (40%) in Group 1, 5 samples (100%) in Group 2 and 1 sample (20%) in Group 3 and was significantly lower in Group 3. However, this difference was not statistically significant (p=0.068) (Table 2).

Table 2.

Comparative Analysis of Histopathological Variables According to Groups

Variables	Control,	CTX,	CTX + stem cell,	p-value
Variables	N = 6	N = 6	N = 5	p-value
Glomerulsclerosis				<0.001
0	3 (60%)	0 (0%)	0 (0%)
1	2 (40%)	0 (0%)	5 (100%)
2	0 (0%)	4 (80%)	0 (0%)
3	0 (0%)	1 (20%)	0 (0%)
Tubular atrophy				0.010
0	2 (40%)	0 (0%)	0 (0%)
1	3 (60%)	0 (0%)	4 (80%)
2	0 (0%)	3 (60%)	1 (20%)
3	0 (0%)	2 (40%)	0 (0%)
Inflammation				0.068
0	3 (60%)	0 (0%)	4 (80%)
1	2 (40%)	5 (100%)	1 (20%)

Histopathological comparison was made between Group 1-control, Group 2-CTX and Group 3-CTX+ stem cell included in the study. In histopathological examination, normal shapes and structures were seen in all areas of the kidney tissues in Group 1. In Group 2, glomeruli shrinkage, Bowman space widening, dilatation, degeneration, and epithelial vacuolization in tubules were observed. In addition, moderate inflammation was observed throughout the entire section. In Group 3, serious regeneration was observed in all areas of the kidney tissue, including an improvement in Bowman spaces; tubular dilatation, epithelial degeneration and vacuolization were also observed to significantly decrease. In caspase-3 staining, normal findings were detected in Group 1, while increased staining was observed in glomeruli and tubular structures in Group 2. In Group 3, a high rate of tubular and glomerular regeneration was observed (Figure 1).

Figure 1.

(A). H&E staining of the kidney (orange arrows indicate renal tubules and black arrows glomeruli). 40×; scale bar = 40 μm. a-Control group, b-CTX group, c-CTX+ stem cell group. H&E staining results showed that CTX group rats exhibited abnormal renal structure, including glomerular shrinkage, renal tubule vacuolization, and renal tubule degeneration. In the CTX + stem cell group, damage to glomeruli and renal tubules was significantly attenuated and regenerating morphology was exhibited. (B) Caspase-3. Active caspase-3 positive cells, which is a marker for apoptosis. Cells with apoptosis are stained brown. a- Control group is observed in normal appearance, a high rate of tubular and glomerular apoptosis is observed. In the b-CTX group and in c-CTX+ stem cell group, a high rate of tubular and glomerular regeneration was observed

Glomerulosclerosis and tubular damage were seen most in Group 2, and this difference was found to be statistically significant (p<0.001; p<0.01) Figure 2.

Figure 2.

It was observed that there was increased glomerulosclerosis and tubular damage in Group 2, and this difference was statistically significant (p<0.001; p<0.01)

Discussion

Since the metabolism enzymes of many drugs are located in the kidneys, these organs are where these agents are excreted from the body and can therefore show toxicity. Cyclophosphamide (CTX) is a drug generally used in chemotherapy, and its metabolites are primarily excreted in the urine. Therefore, it is known that CTX can be toxic to the kidneys. CTX delays the growth of malignant cells due to its toxic metabolites phosphoramide and acrolein. Acrolein inhibits the cellular antioxidant defense cycle and causes the formation of reactive oxygen radicals, including superoxide anions, hydroxyl radicals, and hydrogen peroxide, which cause physiological and morphological changes.²¹ The formation of free radicals causes the disruption of many signaling pathways, including the inflammation pathway and ultimately organ fibrosis.²² This situation has led to the hypothesis that the effects of CTX can be reduced using antioxidant agents. It is known that the mutagenic and cytotoxic effects of cyclophosphamide are specific to proliferating cells only, and that quiescent cells are relatively protected by damage detection mechanisms. However, cyclophosphamide is known to cause severe side effects in high doses and/or long-term use. In today’s nephrology practice, the use of CTX has been significantly restricted. However, it is still used as a steroid-reducing drug in minimal change disease and focal segmental glomerulosclerosis, both in combination with steroids in membranous glomerulonephritis and as the first choice in rapidly progressive glomerulonephritis and certain lupus patients. It is generally recommended to avoid long-term use.²³ Although there are restrictions on its use in nephrology practice, cyclophosphamide is used in the treatment of many malignancies. Since significant beneficial effects are observed in allogeneic or autologous stem cell transplantation applied after cyclophosphamide treatment, the question of whether it may have similar effects on damaged kidney tissues has emerged.

As in tumors, damaged tissues secrete various factors that attract stem cell migration via the CXCL12/CXCR4 axis. Factors that promote stem cell migration include interleukin 8 (IL-8) and transforming growth factor-beta 1 (TGF-β1),²⁴ platelet-derived growth factor (PDGF),²⁵ fibroblast growth factor 2 (FGF-2),²⁶ vascular endothelial growth factor (VEGF),²⁶ and extracellular matrix molecules such as matrix metalloproteinase-2 (MMP-2).²⁷ The primary reparative mechanisms of stem cells include paracrine effects such as angiogenesis,²⁸ anti-apoptosis,²⁸ anti-fibrosis,²⁹ and immunomodulation.³⁰ It is known that exosomes, which are vesicles derived from stem cells that are 30 to 160 nm in size, play an important role in regulating intercellular communication.³¹ It is also known that stem cells have the potential to replace damaged mitochondria in damaged cells and increase cell quality,³² therefore their healing effects on damaged tissues were examined in our study.

The differences between kidney function tests in the samples were first evaluated. However, no significant difference was found between the groups in terms of BUN, urea, or creatinine levels. It is thought that this situation may be because these markers were measured at the 6th week. In similar studies, kidney functions were evaluated in rats given CTX in a shorter period of time. For example, in Uygun et al, kidney function tests were measured 24 hours after cyclophosphamide administration, and significant increases in creatinine and urea were observed in the CTX arm.³³ In a similar study, the protective effects of tolvaptan on CTX treatment were investigated; blood samples were taken one day after CTX administration, and significant increases in creatinine and urea were observed in the CTX arm.³⁴ In a study aiming to reduce the effects of high-dose CTX treatment, the effects of Wuzhi capsules on treatment were investigated; once again, as blood samples were taken at an early stage, urea and creatinine values were found to be significantly higher in the CTX group compared to the control group.³⁵

In many similar studies, urea and creatinine were observed to be significantly higher in the CTX groups compared to the control groups in the samples taken immediately after the completion of the experiment.^36-39 In a study where creatinine, BUN, and urea were measured on the 25th day of cyclophosphamide administration, kidney function tests were found to be significantly higher in the CYS arm.⁴⁰ In our study, taking the samples at the 6th week made a difference in terms of providing information on the late effects of cyclophosphamide on kidney functions. Although BUN, creatinine, and urea levels were higher in the cyclophosphamide arm at the end of the 6th week, this increase was not statistically significant. This situation can be explained by the fact that the acute kidney injury picture started to improve in rats that had experienced an acute kidney injury when there was no repeated dosing. The lack of significant differences in serum BUN and creatinine levels at 6 weeks may be attributed to the late timing of the biochemical analysis, where functional recovery might have occurred despite persistent structural markers.

To observe organ integrity in the event of any damage, pathological indicators can be shown by the deterioration of the structural integrity and shape of the organ. It is known that cyclophosphamide directly induces oxidative stress, causes apoptosis and inflammation, and leads to histopathological conditions.⁴¹ In our study, via hematoxylin-eosin staining, renal integrity was seen to be impaired: There was shrinkage in the glomeruli, widening in the Bowman spaces, dilatation in the renal tubules, and vacuolization in the epithelium and degeneration, especially in the renal tubules. In addition, moderate inflammation was observed in all sections. Stem cell treatment was associated with histopathological improvement.The findings are also consistent with previous studies.^21,35-38

In the group that received stem cell application with the aim of repairing effects on damaged tissues, significant regeneration was observed in the hematoxylin and eosin-stained sections. There was an improvement in glomerular Bowman spaces; and tubular dilatation, epithelial degeneration, and vacuolization had significantly lessened.

Apoptosis, which is a cell collapse characterized by condensation of the cell membrane, shrinkage of the cell, condensation of chromatin and fragmentation of DNA, occurs as a result of reactive oxygen radicals.^42,43 Caspase-3 is considered the main mediator of apoptosis in cells because it initiates the apoptotic process by activating other caspase enzymes, causing fragmentation of DNA and protein structures and condensation of chromatin 44. In our study, while a normal appearance was detected with caspase staining in the control group, a significantly increased uptake in glomerular and tubular structures was observed in the CTX group, and tubular and glomerular regeneration was observed in the CTX+stem cell group. This situation was observed in our study, similar to existing studies.^21,44,45

Today, hUC-MCS is used in the treatment of diseases with nephropathy, such as diabetes mellitus and systemic lupus erythematosus. When applied in the treatment of diabetic nephropathy, it has been observed to reduce the expression of inflammatory cytokines; increase the number of Sertoli cells and rearrange their proteins; and increase the expression of anti-apoptotic proteins in the kidneys.⁴⁶ In studies conducted in diabetic mice, it has been observed that BUN and 24-hour urine albumin excretion significantly decrease after hUC-MCS application.⁴⁷ In lupus nephritis, it is thought that hUC-MCS migration to the kidney is accelerated by CXCL10 synthesized by increased glomerular vascular endothelial cells via the FN-γ/IRF1-KPNA4 pathway. The negative effect of therapeutic effects on the blockade of the CXCL10-CXCR3 pathway also supports this view.⁴⁸ It has also been shown that hUC-MCSs improve lupus nephritis by affecting T and B cell responses.⁴⁹

The use of hUC-MCS treatment in diseases with nephropathy and its beneficial effects shed light on its use in primary and secondary nephropathies. The waste material, a human umbilical cord, was obtained non-invasively; the lack of ethical issues provides an advantage over other sources of stem cells. In addition, the neonatal age of the donor creates a difference in terms of stem cell potency. In our study, it was observed that cyclophosphamide improved the pathological effects and provided significant morphological improvement. These findings suggest that its use in drug-related nephropathies may be beneficial, indicating that it may be worth trying in other nephrological diseases.

The factors affecting the results of the study include the reparative effects of the stem cells administered for therapeutic purposes on the kidney tissue, the duration and frequency of treatment, the number of cells administered for therapeutic purposes, the selected stem cell source, and even the donor selection. Another factor affecting the results is the time elapsed after administration of the stem cell treatment. Changes in kidney tissue after stem cell transplantation may also vary depending on the time of euthanasia.

This study has limitations. Biomarkers were measured at week 6. This late measurement likely missed the acute functional peak of the injury. These findings suggest a potential therapeutic effect that warrants further mechanistic and long-term studies. We believe that these factors explain the different results among studies to some extent. Future studies incorporating molecular markers and long-term functional assessments are needed to elucidate the underlying mechanisms and clinical significance.

Conclusion

Permanent organ damage due to cytotoxic agents used for different purposes has the potential to create serious problems in the future. In this context, the possible nephrotoxic effects of cyclophosphamide, which is used in many cancer treatments, were examined in this study and shown to cause pathologies resulting in glomerulosclerosis and tubular damage. Although no early deviations were detected in laboratory parameters considered as clinical indicators, it is possible that possible failures may occur in the long term. In this context, it has been shown that stem cell applications given together reduce the formation of glomerulosclerosis and tubular damage, and it is thought that this effect may be effective in long-term survival. In the future, it can be expected that these applications will be beneficial in terms of effectiveness within classical protocols in cost-effectiveness studies.

Footnotes

ORCID iD

Aytaj Jafarzade

Ethical Considerations

Written approval from the Gazi University Ethics Committee, was obtained for the study. The study was approved by Gazi University Animal Experiments Local Ethics Committee (Approval number: G.Ü.E.T-66332047-604.01-1015251). All authors have approved the manuscript submission, and the manuscript has not been published. It is not being considered for publication elsewhere, in whole or in part, in any language.

Author Contributions

Muzaffer ÇAYDERE: Pathological examination of tissues and Data collection writer.

Aytaj JAFARZADE: Conception, design, writer, supervision, literature review.

Feyza Bayrakdar Çağlayan: Conception, design, writer, supervision, literature review.

Elvan ANADOL: Animal prosessing and data collection.

Durmuş BURGUCU: Preparation and application of hucMSCs and Data collection.

Canan YILMAZ: Study and analysis of blood samples and Data Collection.

Semih ERGİŞİ: Statistical analysis and interpretation.

Tamer M. MUNGAN: Critical reviewing.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Data Availability Statement

All data generated or analysed during this study are included in this published article and its supplementary information files and the datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.*

Attestation Statement

Animal experiment study.

References

Jiang

Ren

Zhao

Zhou

Ying

Tang

. Ameliorating Effect of Pentadecapeptide Derived from Cyclina sinensis on Cyclophosphamide-Induced Nephrotoxicity. Mar Drugs. 2020;18(9):462. doi:10.3390/md18090462.

Perini

Calabrese

Rinaldi

Gallo

. The safety profile of cyclophosphamide in multiple sclerosis therapy. Expert Opin Drug Saf. 2007;6:183-190.

Uber

Self

Van Bakel

Pereira

. Acute antibody-mediated rejection following heart transplantation. Am J Transplant. 2007;7:2064-2074.

Cengiz

Yeşildağ

Ayhancı

. Siklofosfamid Nedenli Hematoksisite Üzerine Karvakrolün Sitoprotektif Etkileri. TÜTAD. 2018;5(2):125-130. doi:10.19159/tutad.378717.

Zarei

Shivanandappa

. Amelioration of cyclophosphamide-induced hepatotoxicity by the root extract of Decalepis hamiltonii in mice. Food and chemical toxicology. 2013;57:179-184.

Mohammad

Avila

Zhang

, et al. Acrolein cytotoxicity in hepatocytes involves endoplasmic reticulum stress, mitochondrial dysfunction and oxidative stress. Toxicology and applied pharmacology. 2012;265(1):73-82.

Rehman

Tahir

Ali

, et al. Cyclophosphamide-induced nephrotoxicity, genotoxicity, and damage in kidney genomic DNA of Swiss albino mice: the protective effect of Ellagic acid. Mol Cell Biochem. 2012;365(1-2):119-127.

Kang

Jing

Zhang

Hong

Deng

. The Ameliorating Effect of Plasma Protein from Tachypleus tridentatus on Cyclophosphamide-Induced Acute Kidney Injury in Mice. Mar Drugs. 2019;17(4):227.

Cuce

Çetinkaya

Koc

, et al. Chemoprotective effect of vitamin E in cyclophosphamide-induced hepatotoxicity in rats. Chem Biol Interact. 2015;232:7-11. doi:10.1016/j.cbi.2015.02.016.

10.

Nafees

Rashid

Ali

Hasan

Sultana

. Rutin ameliorates cyclophosphamide induced oxidative stress and inflammation in Wistar rats: role of NFκB/MAPK pathway. Chem Biol Interact. 2015;231:98-107. doi:10.1016/j.cbi.2015.02.021.

11.

Mohammed

Tadros

Michel

. Geraniol protects against cyclophosphamide-induced hepatotoxicity in rats: Possible role of MAPK and PPAR-γ signaling pathways. Food Chem Toxicol. 2020;139:111251. doi:10.1016/j.fct.2020.111251.

12.

Liu

Lin

, et al. Paeoniflorin ameliorates renal function in cyclophosphamide-induced mice via AMPK suppressed inflammation and apoptosis. Biomed Pharmacother. 2016;84:1899-1905.

13.

Shi

Pei

Sun

, et al. Optimization of the Flavonoid Extraction Process from the Stem and Leaves of Epimedium Brevicornum and Its Effects on Cyclophosphamide-Induced Renal Injury. Molecules. 2023;29(1):207.

14.

Chakraborty

, et al. Modulation of cyclophosphamide-induced cellular toxicity by diphenylmethyl selenocyanate in vivo, an enzymatic study. J Journal of Cancer Molecules. 2009;4(6):183-189.

15.

Wei

. Stem cell mobilization in multiple myeloma: challenges, strategies, and current developments. Ann Hematol. 2023;102(5):995-1009.

16.

Brown

McKee

Bakshi

, et al. Mesenchymal stem cells: Cell therapy and regeneration potential. J Tissue Eng Regen Med. 2019;13(9):1738-1755. doi:10.1002/term.2914.

17.

Han

Zhang

Han

Chang

Ding

. Mesenchymal Stem Cells for Regenerative Medicine. Cells. 2019;8(8):886. doi:10.3390/cells8080886.

18.

Erceg Ivkošić

Fureš

Ćosić

, et al.

Unlocking the Potential of Mesenchymal Stem Cells in Gynecology: Where Are We Now?

J Pers Med. 2023;13(8):1253.

19.

Tögel

Weiss

, et al. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. J Am Soc Nephrol. 2005;289(1):F31-F42. doi:10.1152/ajprenal.00007.2005.

20.

Semedo

Correa-Costa

Antonio Cenedeze

, et al. Mesenchymal stem cells attenuate renal fibrosis through immune modulation and remodeling properties in a rat remnant kidney model. Stem Cells. 2009;27(12):3063-3073. doi:10.1002/stem.214.

21.

Caglayan

Temel

Kandemir

Yildirim

Kucukler

. Naringin protects against cyclophosphamide-induced hepatotoxicity and nephrotoxicity through modulation of oxidative stress, inflammation, apoptosis, autophagy, and DNA damage. Environ Sci Pollut Res Int. 2018;25(21):20968-20984. doi:10.1007/s11356-018-2242-5.

22.

Meng

X-M

Nikolic-Paterson

Lan

. Inflammatory processes in renal fibrosis. Nature Reviews Nephrology. 2014;10(9):493-503. doi:10.1038/nrneph.2014.114.

23.

Ponticelli

Escoli

Moroni

. Does cyclophosphamide still play a role in glomerular diseases? Autoimmunity Reviews. 2018;17(10):1022-1027.

24.

de Araujo Farias

Carrillo-Galvez

Martin

Anderson

. TGF-beta and mesenchymal stromal cells in regenerative medicine, autoimmunity and cancer. Cytokine Growth Factor Rev. 2018;43:25-37. doi:10.1016/j.cytogfr.2018.06.002.

25.

Ding

Knox

Tschumper

, et al. Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch. Blood. 2010;116:2984-2993. doi:10.1182/blood-2010-02-269894.

26.

Ritter

Perry

Wang

Tang

Bieberich

. Breast cancer cell-derived fibroblast growth factor 2 and vascular endothelial growth factor are chemoattractants for bone marrow stromal stem cells. Ann. Surg. 2008;247:310-314. doi:10.1097/SLA.0b013e31816401d5.

27.

Cronwright

Le Blanc

Götherström

Darcy

Ehnman

Brodin

. Cancer/testis antigen expression in human mesenchymal stem cells: down-regulation of SSX impairs cell migration and matrix metalloproteinase 2 expression. Cancer Res. 2005;65:2207-2215. doi:10.1158/0008-5472.CAN-04-188.

28.

Teng

Wang

. Enhancing angiogenesis and inhibiting apoptosis: evaluating the therapeutic efficacy of bone marrow mesenchymal stem cell-derived exosomes in a DHEA-induced PCOS mouse model. J Ovarian Res. 2024;17(1):121. doi:10.1186/s13048-024-01445-w.

29.

Vanderstichele

Vranckx

. Anti-fibrotic effect of adipose-derived stem cells on fibrotic scars. World J Stem Cells. 2022;14(2):200-213. doi:10.4252/wjsc.v14.i2.200.

30.

. Immunomodulatory effects of mesenchymal stem cell therapy in chronic kidney disease: a literature review. BMC Nephrol. 2025;26(1):107. doi:10.1186/s12882-025-04029-y.

31.

Tan

Wang

Shahzad

Zheng

. Clinical applications of stem cell-derived exosomes. Signal Transduct Target Ther. 2024;9(1):17. doi:10.1038/s41392-023-01704-0.

32.

Zhang

Meng

Han

. Emerging roles of mitochondrial functions and epigenetic changes in the modulation of stem cell fate. Cell. Mol. Life Sci. 2024;81:26. doi:10.1007/s00018-023-05070-6.

33.

Uyumlu

Satılmış

Atıcı

Taşlıdere

. Phenethyl isothiocyanate protects against cyclophosphamide-induced nephrotoxicity via nuclear factor E2-related factor 2 pathway in rats. Exp Biol Med (Maywood). 2023;248(2):157-164.

34.

El‐Shabrawy

Mishriki

Attia

Emad Aboulhoda

Emam

Wanas

. Protective effect of tolvaptan against cyclophosphamide‐induced nephrotoxicity in rat models. Pharmacology Research & Perspectives. 2020;8(5):e00659.

35.

Chen

Xiong

Hou

, et al. Wuzhi capsule regulates chloroacetaldehyde pharmacokinetics behaviour and alleviates high‐dose cyclophosphamide‐induced nephrotoxicity and neurotoxicity in rats. Basic & Clinical Pharmacology & Toxicology. 2019;125(2):142-151.

36.

Mohsin

Akhtar

Alkahtani

, et al. Nephroprotective Effect of Bergapten Against Cyclophosphamide-Mediated Renal Stress, Inflammation, and Fibrosis in Wistar Rats: Probable Role of NF-kB and TGF-β1 Signaling Molecules. ACS Omega. 2024;9(16):18296-18303.

37.

Salama

Nasr

Abdelhakeem

Roshdy

ElGamal

. Alogliptin attenuates cyclophosphamide-induced nephrotoxicity: a novel therapeutic approach through modulating MAP3K/JNK/SMAD3 signaling cascade. Drug and Chemical Toxicology. 2022;45(3):1254-1263.

38.

Gunes

Sahinturk

Uslu

Ayhanci

Kacar

Uyar

. Protective effects of selenium on cyclophosphamide-induced oxidative stress and kidney injury. Biological trace element research. 2018;185:116-123.

39.

Wanas

El‐Shabrawy

Mishriki

Attia

Emam

Aboulhoda

. Nebivolol protects against cyclophosphamide‐induced nephrotoxicity through modulation of oxidative stress, inflammation, and apoptosis. Clinical and Experimental Pharmacology and Physiology. 2021;48(5):811-819.

40.

Alsaidi

Humaish

Alasadi

. Toxic effects of cyclophosphamide on hepatic and kidney tissues in albino mice model. Research Journal of Pharmacy and Technology. 2022;15(10):4655-4659.

41.

Cetinavci

Yenilmez

Firuze Bıyık

Alver

Sağlam

. Rosmarinik asidin sıçanlarda siklofosfamid ile indüklenen nefrotoksisite üzerine etkileri. Cukurova Med. J. 2023;48(3):902-910. doi:10.17826/CUMJ.1317508.

42.

Renehan

Booth

Potten

. What is apoptosis, and why is it important? BMJ. 2001;322(7301):1536-1538. doi:10.1136/bmj.322.7301.1536.

43.

Kim

Lee

Baek

, et al. Mechanism for the protective effect of diallyl disulfide against cyclophosphamide acute urotoxicity in rats. Food Chem Toxicol. 2014;64:110-118.

44.

Fouad

Qutub

Al-Melhim

. Punicalagin alleviates hepatotoxicity in rats challenged with cyclophosphamide. Environ Toxicol Pharmacol. 2016;45:158-162.

45.

Sinanoglu

Yener

Ekici

Midi

Aksungar

. The protective effects of spirulina in cyclophosphamide induced nephrotoxicity and urotoxicity in rats. Urology. 2012;80:1392-13e1. doi:10.1016/j.urology.2012.06.053.

46.

Xiang

Han

Zhang

, et al. Human umbilical cord-derivedmesenchymal stem cells prevent the progression of early diabetic nephropathythrough inhibiting inflammation and fibrosis. Stem Cell Res Ther. 2020;11(1):336-350. doi:10.1186/s13287-020-01852-y.

47.

Xian

Lin

Cao

, et al. Protective effect of umbilical cord mesenchymal stem cells combined with resveratrol against renal podocyte damage in NOD mice. Diabetes Res Clin Pract. 2019;156:107755-107764. doi:10.1016/j.diabres.2019.05.034.

48.

Zhang

Shan

Shen

, et al. Renal remodeling by CXCL10-CXCR3 axis-recruited mesenchymal stem cells and subsequent IL4I1 secretion in lupus nephritis. Signal transduction and targeted therapy. 2024;9(1):325. doi:10.1038/s41392-024-02018-5.

49.

Mao

, et al. Mesenchymal stem cells-derived extracellular vesicles ameliorate lupus nephritis by regulating T and B cell responses. Stem cell research & therapy. 2024;15(1):216. doi:10.1186/s13287-024-03834-w.

The Effect of Stemcell Treatment on Nephrotoxicity Developing After Cyclophosphamide Treatment

Abstract

Objectives

Material and Methods

Result

Conclusion

Keywords

Introduction

Material and Methods

Formation of Cyclophosphamide-Induced Kidney Injury Model and Administration of h-USMSC

Ethical Approval

Isolation and Characterization of h-USMSC

Primary Culture

Mesenchymal Stem Cell Immunophenotyping

Histological Examination of Rat Kidneys

Elisa

Statistical Analysis

Results

Discussion

Conclusion

Footnotes

ORCID iD

Ethical Considerations

Author Contributions

Funding

Declaration of Conflicting Interests

Data Availability Statement

Attestation Statement

References